Study phase | Case | Baseline study eye | Week 24 study eye | Baseline fellow eye | Week 24 fellow eye | Baseline asymmetry | Week 24 asymmetry |
A: Teprotumumab group | |||||||
3 | 1 | 28 | 28 | 24 | 24 | 4 | 4 |
3 | 2 | 21 | 19 | 18 | 18 | 3 | 1 |
3 | 3 | 20 | 20 | 17 | 18 | 3 | 2 |
3 | 4 | 25 | 26 | 22 | 23 | 3 | 3 |
3 | 5 | 21 | 21 | 17 | 18 | 4 | 3 |
3 | 6 | 24 | 23.5 | 19 | 20 | 5 | 4 |
2 | 7 | 24 | 21 | 21 | 19 | 3 | 2 |
2 | 8 | 16 | 16.5 | 12 | 16 | 4 | 1 |
2 | 9 | 19 | 21 | 16 | 17 | 3 | 4 |
2 | 10 | 28 | 30 | 25 | 25 | 3 | 5 |
2 | 11 | 25 | 25 | 22 | 23 | 3 | 2 |
2 | 12 | 22 | 23 | 18 | 17 | 4 | 6 |
Mean | 22.8 | 22.8 | 19.3 | 19.8 | 3.5 | 3.1 | |
SD | 3.6 | 3.9 | 3.7 | 3.1 | 0.7 | 1.6 | |
B: Placebo group | |||||||
3 | 1 | 28 | 28 | 24 | 24 | 4 | 4 |
3 | 2 | 21 | 19 | 18 | 18 | 3 | 1 |
3 | 3 | 20 | 20 | 17 | 18 | 3 | 2 |
3 | 4 | 25 | 26 | 22 | 23 | 3 | 3 |
3 | 5 | 21 | 21 | 17 | 18 | 4 | 3 |
3 | 6 | 24 | 23.5 | 19 | 20 | 5 | 4 |
2 | 7 | 24 | 21 | 21 | 19 | 3 | 2 |
2 | 8 | 16 | 16.5 | 12 | 16 | 4 | 1 |
2 | 9 | 19 | 21 | 16 | 17 | 3 | 4 |
2 | 10 | 28 | 30 | 25 | 25 | 3 | 5 |
2 | 11 | 25 | 25 | 22 | 23 | 3 | 2 |
2 | 12 | 22 | 23 | 18 | 17 | 4 | 6 |
Mean | 22.8 | 22.8 | 19.3 | 19.8 | 3.5 | 3.1 | |
SD | 3.6 | 3.9 | 3.7 | 3.1 | 0.7 | 1.6 |